Immuron has submitted an IND application to the FDA for clinical development of IMM-529 to specifically prevent or treat Clostridioides difficile infection (CDI). A Phase 2 clinical trial is planned for the first half of 2026, with potential annual revenue projected at approximately US$400M. IMM-529 targets essential virulence components of C. diff, with the potential to accelerate infection clearance and restore healthy gut microbiota. It is the only investigational drug showing promise in all phases of CDI. The Company is collaborating with Monash University to develop vaccines against C. diff virulence components. Investors are encouraged to ask any questions they may have about this key milestone for Immuron. For more information, visit our website at www.immuron.com.au and feel free to sign up for updates on our Investor Hub. Please note that forward-looking statements are subject to risks and uncertainties that could impact our business and financial outcomes. We will continue to provide updates as required by law. Thank you for your interest in Immuron.